Company Overview - Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel class of therapeutic biologics aimed at selectively engaging and modulating disease-specific T cells for cancer and autoimmune disease treatment [1][3] - The company utilizes its proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), to harness the immune system's potential while minimizing adverse effects associated with broad systemic immune modulation [3] Upcoming Event - Cue Biopharma will participate in an unplugged fireside discussion at the Piper Sandler 36th Annual Healthcare Conference in New York from December 3-5, 2024 [1] - The discussion is scheduled for December 4, 2024, from 9 a.m. to 9:25 a.m. EST, where the company will provide updates on recent clinical and preclinical programs, as well as strategic business and partnering objectives [2] Management and Expertise - The company is headquartered in Boston, Massachusetts, and is led by an experienced management team and independent Board of Directors with extensive expertise in immunology, immuno-oncology, and the clinical development of protein biologics [4]
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference